The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and developing …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …

Abstract Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive
histologic subtype of prostate cancer that most commonly arises in later stages of prostate …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

The cancer transcriptome is remarkably complex, including low-abundance transcripts,
many not polyadenylated. To fully characterize the transcriptome of localized prostate …